Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:GRAL

GRAIL Q3 2026 Earnings Date & Estimates

GRAIL logo
$135.46 -4.24 (-3.04%)
Closing price 10/15/2026 04:00 PM Eastern
Extended Trading
$137.00 +1.54 (+1.14%)
As of 06:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRAIL is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from GRAIL in Q3 2026

GRAIL is expected to post earnings of -$2.5017 per share on revenue of $44.21 million. In the same quarter a year earlier GRAIL reported -$2.46 per share on revenue of $36.19 million. GRAIL last reported on August 5, 2026, posting -$2.56 per share and beating the -$2.66 consensus estimate. GRAIL has beaten the consensus EPS estimate in 6 of its last 7 quarters.

Consensus Estimates

Consensus EPS
-$2.5017
Expected Revenue
$44.21 million
Prior-Year EPS
-$2.46
Prior-Year Revenue
$36.19 million
Expected Revenue Growth
+22.1%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$2.56 (Beat by +$0.10)
Last Quarter Revenue
$44.69 million
EPS Beat Rate
6 of last 7 quarters

Prepare for the Q3 2026 Call

GRAIL Q3 2026 Earnings FAQ

GRAIL (NASDAQ:GRAL) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

GRAIL's Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect GRAIL to post earnings of -$2.5017 per share for Q3 2026.

The consensus revenue estimate for GRAIL is $44.21 million for Q3 2026.

GRAIL Earnings Headlines

TD Cowen Forecasts Strong Price Appreciation for GRAIL (NASDAQ:GRAL) Stock
October 15 at 2:06 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31120715
Morgan Stanley Sticks to Their Hold Rating for GRAIL Inc (GRAL)
October 14 at 12:09 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/GRAL/pressreleases/7594743/morgan-stanley-sticks-to-their-hold-rating-for-grail-inc-gral/
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
October 16 at 1:00 AM  |  Stansberry Research (Ad)
First-Class Amenity Kits Have Become Holy Grail Collectibles
October 12, 2026  |  wsj.comhttps://www.wsj.com/lifestyle/travel/first-class-amenity-kits-have-become-holy-grail-collectibles-adfbb1a0
Keith McCullough's GRAL call meets insider sales (GRAL)
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31108990
Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.
October 11, 2026  |  fool.comhttps://www.fool.com/investing/2026/10/11/grail-stock-hit-12-month-high-fda-panel-win-risk/
See More GRAIL Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GRAIL? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GRAIL and other key companies, straight to your email.

About GRAIL

GRAIL (NASDAQ:GRAL) is a healthcare company focused on developing blood-based technologies for the early detection of cancer. Its goal is to identify cancer signals before symptoms appear, when treatment may be more effective, by applying genomics, machine learning and other analytical methods to blood samples.

The company’s primary product is the Galleri multi-cancer early detection test, a prescription laboratory-developed test designed to screen for signals associated with multiple types of cancer from a single blood draw. When a cancer signal is detected, the test may also provide information intended to help guide diagnostic follow-up. Galleri is not intended to replace recommended cancer screenings, and it has not been approved or cleared by the U.S. Food and Drug Administration.

GRAIL was founded in 2016 with backing from Illumina, a provider of genomic sequencing technologies, and later operated as an independent publicly traded company. The company primarily serves the U.S. market through healthcare providers and other channels, while conducting research and commercial activities related to early cancer detection in additional geographies. GRAIL is led by Chief Executive Officer Bob Ragusa.

View GRAIL Profile
Earnings Tools